Skip to main content
Signal8

Dogwood Therapeutics, Inc. (DWTX) Form 10-Q — May 15, 2026

$DWTXForm 10-QFiled May 15, 2026, 9:20 AM ET0001104659-26-061938Original filing

Dogwood Therapeutics reported a net loss of $4.99 million for Q1 2026, driven by $2.67 million in R&D and $2.41 million in G&A expenses, with no product revenue generated to date. The company holds $13.2 million in cash, bolstered by a $12.5 million capital raise in January 2026, but explicitly states this is insufficient to fund operations beyond the fourth quarter of 2026. The filing includes a going concern warning, noting substantial doubt about the company's ability to continue as a going concern within 12 months without additional dilutive financing.

Key figures

Revenue
0
Total Debt
0
Total Assets
95207871
Cash Position
13227839
Shares Outstanding
33629553
Ga Expense Q1
2406587
Rd Expense Q1
2669779
Iprd Carrying Value
67831894
Net Proceeds Jan2026
11400000
Gross Proceeds Jan2026
12500000
Goodwill Carrying Value
12193825

Price after filing

1 day: 0.0%7 days: -8.6%30 days: -20.7%

Close on the filing date to close N calendar days later (from $1.98). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.